Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

Archives of Neurology

Volumn 66, Issue 12, 2009, Pages 1469-1475

  Morris, John C ^a   Roe, Catherine M ^a   Grant, Elizabeth A ^a,b   Head, Denise ^a,b   Storandt, Martha ^a,b   Goate, Alison M ^a   Fagan, Anne M ^a   Holtzman, David M ^a   Mintun, Mark A ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CONTRAST MEDIUM; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DEPTH PERCEPTION; DISEASE COURSE; DRUG BINDING; DRUG UPTAKE; ENTORHINAL CORTEX; EPISODIC MEMORY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEMANTIC MEMORY; SUBICULUM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANILINE COMPOUNDS; CARBON RADIOISOTOPES; COGNITION; COGNITION DISORDERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; THIAZOLES;

EID: 73549092137     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.269     Document Type: Article

References (59)

1. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358-368.
2. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW Jr, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001;58(9):1395-1402.
3. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62(11):1087-1095.
4. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837-1844.
5. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026-1036.
6. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-234.
7. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631-639.
8. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
9. 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.
10. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
11. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326-335.
12. Coats M, Morris JC. Antecedent biomarkers of Alzheimer's disease: The Adult Children Study. J Geriatr Psychiatry Neurol. 2005;18(4):242-244.
13. Morris JC, McKeel DW Jr, Storandt M, et al. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathological distinction from normal aging. Neurology. 1991;41(4):469-478.
14. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathological outcomes in original versus revised MCI and in PreMCI. Neurology. 2006;67(3):467-473.
15. Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res. 1975;12(3):189-198.
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
17. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210-216.
18. American Psychiatric Association. DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
19. Wechsler D, Stone CP. Manual: Wechsler Memory Scale. New York, NY: Psychological Corporation; 1973.
20. Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. Neurology. 2000;54(4):827-832.
21. Wechsler D. Manual: Wechsler Adult Intelligence Scale. New York, NY: Psychological Corporation; 1955.
22. Goodglass H, Kaplan E. Boston Naming Test Scoring Booklet. Philadelphia, PA: Lea & Febiger; 1983.
23. Thurstone LL, Thurstone LG. Examiner Manual for the SRA Primary Mental Abilities Test. Chicago, IL: Science Research Associates; 1949.
24. Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psychol Monogr. 1946;60:1-48.
25. Johnson DK, Storandt M, Morris J, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol. 2009;66(10):1254-1259.
26. Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage. 2004;23(2):724-738.
27. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-980.
28. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss are signatures of cerebral amyloid-β peptide deposition identified with Pittsburgh Compound B: cognitive decline associated with Aβ deposition. Arch Neurol. 2009;66(12):1476-1481.
29. Head D, Snyder AZ, Girton LE, Morris JC, Buckner RL. Frontal-hippocampal double dissociation between normal aging and Alzheimer's disease. Cereb Cortex. 2005;15(6):732-739.
30. Jovicich J, Czanner S, Han X, et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage. 2009;46(1):177-192.
31. Mintun MA, LaRossa GN, Sheline YI, et al. [11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
32. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740-2754.
33. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain: 3-D Proportional System: An Approach to Cerebral Imaging. Stuttgart, Germany: Thieme Medical Publishers; 1988.
34. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834-840.
35. Pastor P, Roe CM, Villegas A, et al. Apolipoprotein E?4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54(2):163-169.
36. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid AB42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176-183.
37. Morris JC, Roe CM, Xiong C, et al. APOE predicts Aβ but not tau Alzheimer's pathology in cognitively normal aging [published online ahead of print August 21, 2009]. Ann Neurol. doi:10.1002/ana.21843.
38. Cairns NJ, Ikonomovic MD, Benziger T, et al. Absence of Pittsburgh Compound B detection of cerebral amyloid β in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66(12):1557-1562.
39. Rowe CC, Ng S, Ackermann U, et al. Imaging B-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725.
40. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(pt 11):2837-2844.
41. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
42. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38(4):643-648.
43. Sunderland T, Linker G, Mirza N, et al. Decreased β-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289(16):2094-2103.
44. Clark CM, Xie S, Chittams J, et al. CSF tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60(12):1696-1702.
45. Tapiola T, Alafuzoff I, Herukka S-K, et al. Cerebrospinal fluid B-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382-389.
46. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol. 2006;59(3):512-519.
47. Petrie EC, Cross DJ, Galasko D, et al. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol. 2009;66(5):632-637.
48. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497-510.
49. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol. 2008;65(11):1467-1471.
50. Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer's disease, and reserve. Arch Neurol. 2008;65(1):113-120.
51. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15(3):169-176.
52. Herukka S-K, Hallikainen M, Soininen H, Pirttila T. CSF AB42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64(7):1294-1297.
53. Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI. Neurology. 2007;69(24):2205-2212.
54. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619-627.]
55. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456-1465.
56. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65(5):557-568.
57. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents earlystage Alzheimer's disease. Arch Neurol. 2001;58(3):397-405.
58. Du AT, Schuff N, Kramer JH, et al. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology. 2004;62(3):422-427.
59. Stoub TR, Bulgakova M, Leurgans S, et al. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology. 2005;64(9):1520-1524.